Company Encyclopedia
View More
name
BiomX
PHGE.US
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
1.902 T
PHGE.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BiomX Ltd. Files for Insolvency After Halting Phase 2b Study

    BiomX Ltd., an Israeli subsidiary of BiomX Inc., has filed for insolvency following the halt of its Phase 2b study due to limited financial resources. The parent company is exploring strategic options and retains ownership of its BX011 program for diabetic foot infections, managed by Adaptive Phage Therapeutics, Inc. This information was originally published by BiomX Inc. via the U.S. SEC's EDGAR system.

    Reuters·
    US
    PHGE
    -6.94%
    Reuters·
    US
    PHGE
    -6.94%

    U.S. Stock Market Midday Update: Termination of Trial Layoff Plan Draws Attention, BiomX Stock Price Rises 12.91% Against the Trend

    BiomX rose 12.91%; AbbVie rose 0.39%, with a trading volume of USD 550 million; Abivax SA rose 3.34%, with a trading volume of USD 381 million; Regeneron Pharmaceuticals rose 2.92%, with a trading volume of USD 314 million; Amgen rose 0.69%, with a market capitalization of USD 170.2 billion

    Tracking Unusual Activity·
    US
    PHGE
    -6.94%
    Tracking Unusual Activity·
    US
    PHGE
    -6.94%

    Sector Update: Health Care Stocks Fall Late Afternoon

    Health care stocks fell late Monday afternoon, with the NYSE Health Care Index down 1.1% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.2%. Kamada shares decreased 5% due to discontinuing a trial, BiomX tumbled 36% after halting a phase 2b trial, STAAR Surgical fell 7% post-merger period expiration, and PROCEPT BioRobotics dropped 4.5% following a stock downgrade by BofA Securities.

    fidelity·
    US
    STAA
    -2.23%
    US
    PRCT
    -0.11%
    US
    PHGE
    -6.94%
    fidelity·
    US
    STAA
    -2.23%
    US
    PRCT
    -0.11%
    US
    PHGE
    -6.94%

    BiomX Discontinues Cystic Fibrosis Program and Reduces Workforce

    BiomX Inc. has discontinued its Phase 2b clinical trial of BX004 for Cystic Fibrosis due to resource constraints. The company will cut costs by reducing its workforce and focus on advancing BX011 for diabetic foot infections, pending financial resources. BiomX is also reviewing other strategic alternatives.

    Reuters·
    US
    PHGE
    -6.94%
    Reuters·
    US
    PHGE
    -6.94%

    PHGE shares are trading lower after the company discontinued its Phase 2b trial of BX004 in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.

    benzinga_article·
    US
    PHGE
    -6.94%
    benzinga_article·
    US
    PHGE
    -6.94%
    © 2025 Longbridge｜Disclaimer